Comparison of the Effect of the Combination of Sodium Valproate and Sodium Dichloroacetate on the Expression of SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP in Primary Female Glioblastoma Cells with That of Temozolomide

The search for an effective treatment for adult high-grade glioblastoma (GBM) remains urgent. <b>Background/Objectives</b>: The study aimed to determine the expression of carcinogenesis-related genes, such as <i>SLC12A2</i>, <i>SLC12A5</i>, <i>CDH1</i>, <i>CDH2</i>, <i>EZH2</i>, and <i>GFAP</i>, in primary glioblastoma (WHO Grade IV; IDH-wild-type) cells from three adult women: GBM5-1, GBM5-2F, and GBM5-3F. <b>Methods</b>: The impact of the combination of sodium valproate and sodium dichloroacetate (2 mM NaVPA-3 mM NaDCA) on the expression of these genes was determined and compared with the effects of 50 µM temozolomide after 24 h of treatment. <b>Results</b>: 2 mM NaVPA-3 mM NaDCA, as well as temozolomide, had individual impacts on the <i>SLC12A2</i>, <i>SLC12A5</i>, <i>CDH1</i>, <i>CDH2</i>, <i>EZH2</i>, and <i>GFAP</i> expressions of tested GBM5-1, GBM5-2F, and GBM5-3F primary cells of female GBM patients. <b>Conclusions</b>: The combination of 2 mM NaVPA-3 mM NaDCA may have an advantage in antitumor activity and may be more effective than TMZ; however, the effect is individual.